Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline
Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target class Initial discovery pipeline focused on high-value